RPR TAXOTERE NDA RE-FILING IN 1997 IS TARGET FOLLOWING REJECTION BY FDA ADVISORY COMMITTEE; DOCETAXEL TOXICITY CONCERNS REQUIRE PHASE III STUDY
Executive Summary
Rhone-Poulenc Rorer will re-file its application for Taxotere (docetaxel) for breast and non-small cell lung cancers in early 1997, Senior VP-Pharmaceuticals Drug Development Gary Shearman, PhD, forecast at a press conference following the Dec. 13 advisory committee review of the application.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth